ADVFN Logo ADVFN

Hot Features

Registration Strip Icon for discussion 登録して、同じ考えを持つ投資家と議論するためのアクティブなフォーラムで相互作用するためのアクティブなフォーラムに参加してください。
44.05
-0.80
(-1.78%)
終了 1月26日 6:00AM
44.05
-0.01
(-0.02%)
取引時間後: 7:30AM

リアルタイムのストリーミング引用、アイデア、ライブディスカッションのハブ

主要統計と詳細

通貨
44.05
買値
37.07
売値
46.59
出来高
763,018
44.03 日の範囲 45.2692
37.02 52 週間の範囲 60.37
時価総額
前日終値
44.85
始値
44.81
最終取引時間
財務取引量
US$ 34,074,887
VWAP
44.658
平均取引量 (3 か月)
910,812
発行済株式数
92,344,268
配当利回り
-
PER
-6.71
1 株当たり利益 (EPS)
-6.57
歳入
434.25M
純利益
-606.64M

Ultragenyx Pharmaceutical Inc について

Ultragenyx Pharmaceutical Inc is a US-based biopharmaceutical company. It identifies, acquires, develops, and commercialize novel products for the treatment of serious rare and ultra-rare diseases, with the focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Cr... Ultragenyx Pharmaceutical Inc is a US-based biopharmaceutical company. It identifies, acquires, develops, and commercialize novel products for the treatment of serious rare and ultra-rare diseases, with the focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. 詳細を表示

セクター
Pharmaceutical Preparations
業界
Pharmaceutical Preparations
ウェブサイト
本社
Wilmington, Delaware, USA
設立
-
Ultragenyx Pharmaceutical Inc is listed in the Pharmaceutical Preparations sector of the ナスダック市場 with ticker RARE. The last closing price for Ultragenyx Pharmaceutical was US$44.85. Over the last year, Ultragenyx Pharmaceutical shares have traded in a share price range of US$ 37.02 to US$ 60.37.

Ultragenyx Pharmaceutical currently has 92,344,268 shares in issue. The market capitalisation of Ultragenyx Pharmaceutical is US$4.14 billion. Ultragenyx Pharmaceutical has a price to earnings ratio (PE ratio) of -6.71.

RARE 最新ニュース

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

NOVATO, Calif., Jan. 17, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies...

Ultragenyx Reports Preliminary 2024 Revenue, Financial Guidance for 2025, Pipeline Updates, and 2025 Milestones

Preliminary 2024 total revenue of $555 million to $560 million, exceeding top end of guidance, including Crysvita® revenue of $405 million to $410 million, and Dojolvi® revenue of $87 million to...

Ultragenyx to Present at the 43rd Annual J.P. Morgan Healthcare Conference

NOVATO, Calif., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies...

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

NOVATO, Calif., Dec. 20, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies...

Ultragenyx Announces First Patient Dosed in Pivotal Phase 3 Aspire Study Evaluating GTX-102 in Angelman Syndrome

NOVATO, Calif., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), today announced that the first patient has been dosed in the pivotal Phase 3 Aspire study...

Ultragenyx Submits Biologics License Application to the U.S. FDA for UX111 AAV Gene Therapy for the Treatment of Sanfilippo Syndrome Type A (MPS IIIA)

NOVATO, Calif., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug...

期間 †前日比前日比 %始値高値安値平均出来高VWAP
12.836.8655992236841.2244.0639.9991910641.39098026CS
40.2450.55929688391743.80546.2439.79109484642.07179828CS
12-7.09-13.863903011351.1453.239.7991081245.57769174CS
26-0.84-1.8712408108744.8960.3739.7977777049.46900501CS
52-0.91-2.0240213523144.9660.3737.0277886746.82270593CS
156-21.67-32.9732197265.7285.5331.5271507346.25444531CS
260-13.78-23.828462735657.83179.64731.5261730760.22709008CS

RARE - Frequently Asked Questions (FAQ)

What is the current Ultragenyx Pharmaceutical share price?
The current share price of Ultragenyx Pharmaceutical is US$ 44.05
How many Ultragenyx Pharmaceutical shares are in issue?
Ultragenyx Pharmaceutical has 92,344,268 shares in issue
What is the market cap of Ultragenyx Pharmaceutical?
The market capitalisation of Ultragenyx Pharmaceutical is USD 4.14B
What is the 1 year trading range for Ultragenyx Pharmaceutical share price?
Ultragenyx Pharmaceutical has traded in the range of US$ 37.02 to US$ 60.37 during the past year
What is the PE ratio of Ultragenyx Pharmaceutical?
The price to earnings ratio of Ultragenyx Pharmaceutical is -6.71
What is the cash to sales ratio of Ultragenyx Pharmaceutical?
The cash to sales ratio of Ultragenyx Pharmaceutical is 9.37
What is the reporting currency for Ultragenyx Pharmaceutical?
Ultragenyx Pharmaceutical reports financial results in USD
What is the latest annual turnover for Ultragenyx Pharmaceutical?
The latest annual turnover of Ultragenyx Pharmaceutical is USD 434.25M
What is the latest annual profit for Ultragenyx Pharmaceutical?
The latest annual profit of Ultragenyx Pharmaceutical is USD -606.64M
What is the registered address of Ultragenyx Pharmaceutical?
The registered address for Ultragenyx Pharmaceutical is CORPORATION TRUST CENTER, 1209 ORANGE ST, WILMINGTON, DELAWARE, 19801
What is the Ultragenyx Pharmaceutical website address?
The website address for Ultragenyx Pharmaceutical is www.ultragenyx.com
Which industry sector does Ultragenyx Pharmaceutical operate in?
Ultragenyx Pharmaceutical operates in the PHARMACEUTICAL PREPARATIONS sector

ムーバー

すべて表示
  • 出来高
  • 値上がり率
  • 値下がり率
銘柄コード株価出来高
NVNINVNI Group Ltd
US$ 4.38
(193.96%)
366.98M
EVAXEvaxion Biotech AS
US$ 5.99
(64.56%)
55.41M
ELABPMGC Holdings Inc
US$ 3.0901
(56.07%)
76.48M
PCLAPicoCELA Inc
US$ 4.60
(49.35%)
3.75M
GOEVCanoo Inc
US$ 0.475
(43.94%)
282.22M
GODNUGolden Star Acquisition Corporation
US$ 3.11
(-75.82%)
17.51k
GODNGolden Star Acquisition Corporation
US$ 2.93
(-65.67%)
902.76k
NXTTNext Technology Holding Inc
US$ 1.37
(-54.93%)
2.56M
SGLYSingularity Future Technology Ltd
US$ 1.625
(-38.45%)
917.77k
WHLRLWheeler Real Estate Investment Trust Inc
US$ 90.11
(-38.07%)
8
ACONAclarion Inc
US$ 0.0557
(28.94%)
811.91M
NVNINVNI Group Ltd
US$ 4.38
(193.96%)
366.98M
RIMEAlgorhythm Holdings Inc
US$ 0.0357
(4.69%)
284.97M
GOEVCanoo Inc
US$ 0.475
(43.94%)
282.22M
NVDANVIDIA Corporation
US$ 142.62
(-3.12%)
232.88M

RARE Discussion

投稿を表示

最近閲覧した銘柄

Delayed Upgrade Clock